




Figure S1: Body weight of mice treated with mAb104-ADCs




Figure S2: Pharmacodynamic analysis by Immunohistochemistry of necrosis, pH2A.X, cleaved caspase 3 and ki67 in lung cancer xenograft NCI-H2170




Figure S3: Pharmacodynamic analysis by Immunohistochemistry of necrosis, pH2A.X, cleaved caspase 3 and ki67 in lung cancer xenograft NCI-H1650






Figure S4: Pharmacodynamic analysis by Western blot of mAb104-DX8951 effects on HER2 and known HER2 effector pathways in NCI-H2170 xenograft tumours


Supplementary Figure. Uncropped blots and densitometry analysis for **Figure S4 (A)** for pH2AX, pHER2, pAKT, pERK1/2, GAPDH, HER2, AKT, ERK1/2 from NCI-H2170 week 2 tumor samples.



	pH2AX/GAPDH
IgG1	0.3627
	0.8205
	0.9478
mAb104	0.8250
	0.5122
Trastuzumab	0.1949
	0.5210
TDM1	0.2504
	0.1697
IgG1-DX8951	0.4208
	0.2838
mAb104-DX8951	0.1564
	0.0909




	pHER2/GAPDH	pAKT/GAPDH	pERK/GAPDH
IgG1	0.0959	0.3514	0.4267
	0.0510	0.5562	0.2290
	0.0364	0.4445	0.1769
mAb104	0.0778	0.2472	0.1885
	0.0705	0.2393	0.2396
Trastuzumab	0.1617	0.2050	0.1845
	0.1671	0.0886	0.1362
TDM1	0.0548	0.2382	0.5389
	0.0274	0.2451	0.4580
IgG1-DX8951	0.0857	0.3143	0.1943
	0.0884	0.5616	0.4492
mAb104-DX8951	0.0420	0.6430	0.5400
	0.0462	0.7676	0.7381



	HER2/GAPDH	AKT/GAPDH	ERK/GAPDH
IgG1	2.3174	1.2292	2.8897
	1.4254	1.3123	2.5305
	1.1079	0.8562	1.5294
mAb104	0.6725	0.8235	1.3338
	0.8022	0.7221	0.8493
Trastuzumab	1.0993	0.8517	1.3590
	1.0989	0.6886	0.9525
TDM1	1.2755	0.7740	1.1666
	1.5714	0.9648	1.4327
IgG1-DX8951	2.6453	1.1770	2.0286
	3.3991	1.5720	3.1430
mAb104-DX8951	3.5652	2.1515	3.0390
	3.5154	1.9620	2.8936

Supplementray Figure. Uncropped blots and densitometry analysis for **Figure S4 (B)** for pH2AX, pHER2, pAKT, pERK1/2, GAPDH, HER2, AKT, ERK1/2 from NCI-H2170 week 3 tumor samples.








Figure S5: Pharmacodynamic analysis by Western blot of mAb104-DX8951 effects on HER2 and known HER2 effector pathways in NCI-H1650 xenograft tumours


Supplementary Figure. Uncropped blots and densitometry analysis for **Figure S5 (A)** for pH2AX, pAKT, pERK1/2, GAPDH, HER2, AKT, ERK1/2 from NCI-H1650 week 2 tumor samples.




Supplementary Figure . Uncropped blots and densitometry analysis for **Figure S5 (B)** for pH2AX, pAKT, pERK1/2, GAPDH, HER2, AKT, ERK1/2 from NCI-H1650 week 3 tumor samples.



	pH2AX/GAPDH
IgG1	0.0370
	0.4824
	0.9322
104	0.2492
	0.2733
Tras	0.6131
	0.3967
TDM1	1.2001
	0.2611
IgG1-DX8951	0.9395
	0.0402
mAb104-DX8951	0.0164
	0.1167



	pAKT/GAPDH	pERK/GAPDH
IgG1	1.0890	1.4447
	1.4107	1.5407
	1.3244	2.0086
104	0.8874	1.0666
	1.4808	1.8816
Tras	1.4521	2.0397
	0.5541	0.6172
TDM1	1.7019	2.3997
	1.6253	2.1353
IgG1-DX8951	1.2777	1.5497
	1.0731	1.3352
mAb104-DX8951	1.8521	2.1317
	1.1524	1.7461



	HER2/GAPDH	AKT/GAPDH	ERK/GAPDH
IgG1	0.8212	4.0054	2.2105
	0.2416	2.0341	2.4146
	0.1754	1.6526	2.6141
104	0.1924	0.9466	1.4398
	0.3716	1.4953	2.4319
Tras	0.2031	1.6364	3.1299
	0.1270	0.6297	1.2678
TDM1	0.1701	1.1062	2.9535
	0.1627	0.7839	2.2152
IgG1-DX8951	0.1421	0.7391	1.8127
	0.2135	1.2298	2.4852
mAb104-DX8951	0.5440	1.9059	3.0732
	0.3577	1.6857	2.3678